Noxon

Drug Development for Fibrotic Lung Diseases

Active Pre-Seed Startup Nazareth Founded 2023-01

Noxon develops a novel drug for oral treatment of fibrotic lung diseases. The developed drug, 3-cabamoyl-proxyl, is a stable organic radical belonging to the nitroxides group. Its product, 3-CP, which has a unique antioxidant property, has been shown to reduce airway inflammation, airway hyper-responsiveness, and other inflammatory mediators of the lung tis…

SectorHealth Tech & Life Sciences
StagePre-Seed
Employees6
Founded2023-01
HQNazareth
Confidence87
Sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technology
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals